ADA: No Cancer Risk with Lantus (CME/CE, with video)
11:04 EDT 12 Jun 2012 | MedPageToday
PHILADELPHIA (MedPage Today) -- Three observational studies showed no increased risk of cancer with use of insulin glargine (Lantus) compared with other insulins in the short term, researchers reported here.
Original Article: ADA: No Cancer Risk with Lantus (CME/CE, with video)
More From BioPortfolio on "ADA: No Cancer Risk with Lantus (CME/CE, with video)"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
